Filing Details

Accession Number:
0001209191-23-044838
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-07 16:51:33
Reporting Period:
2023-08-04
Accepted Time:
2023-08-07 16:51:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1786205 Arcellx Inc. ACLX Biological Products, (No Disgnostic Substances) (2836) 472855917
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1789632 Christopher Heery C/O Arcellx, Inc.
25 West Watkins Mill Road, Suite A
Gaithersburg MD 20878
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-04 3,000 $15.00 10,795 No 4 M Direct
Common Stock Disposition 2023-08-04 3,000 $35.38 7,795 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Disposition 2023-08-04 3,000 $0.00 3,000 $15.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
215,205 2032-02-03 No 4 M Direct
Footnotes
  1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022.
  2. Represents the weighted average share price of an aggregate total of 3,000 shares sold in the price range of $35.00 to $35.98 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022.